Asanka S. Yapa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asanka S. Yapa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alexander Kozikowski
Chembio Diagnostics Inc., Research & Development, Medford, USA
1 shared publication- Angelo H. Gunasekera
Chembio Diagnostics Inc., Research & Development, Medford, USA
1 shared publication Cheng Yang
Takeda Pharmaceutical Company Limited, Diagnostic Devices Center of Excellence, Cambridge, USA
1 shared publicationClaudia Villa
Chembio Diagnostics Inc., Research & Development, Medford, USA
1 shared publicationDeryl L. Troyer
Department of Anatomy & Physiology, Kansas State University, Manhattan, KS 66506, USA
1 shared publication- Dinusha N. Udukala
Department of Chemistry, Kansas State University, Manhattan, KS 66506, USA
1 shared publication
Latest Publications
- 21 August 2025
- Published by Springer Nature in Gene Therapy
- Vol. 32 (6) , 610-620
Rapid detection of AAV8 binding antibodies in gene therapy candidates: development of a point-of-care approach
Preexisting anti-AAV antibodies pose a significant challenge to the success of Adeno-associated Virus (AAV) mediated gene therapies, as they can diminish therapeutic effectiveness, restrict patient eligibility for treatment, and cause serious health issues during treatment. This study introduces the first point-of-care (POC) test for the rapid, quantitative detection of AAV8 binding antibodies in patients’ plasma, serum, and blood, leveraging Chembio’s Dual Path Platform (DPP) technology. The DPP AAV8 Total Antibody (TAb) assay delivers results within 20 min from sample addition, with a dynamic range of 0-32 µg/ml when evaluated with purified human polyclonal antibodies that bind to AAV8, with reasonable specificity and sensitivity relative to Chembio’s AAV8 TAb ELISA (R² = 0.90). Moreover, the assay demonstrated strong correlations with Chembio’s AAV8 neutralizing antibody (NAb) ELISA and cell-based NAb assays (R² = 0.97 in plasma) (Cell-based assay adapted from BioAgilytix EU protocol). This rapid and reliable test can facilitate the screening of potential gene therapy patients for pre-existing antibodies that bind to AAV8 and assess their suitability for AAV8-mediated gene therapy.
- 21 August 2025
- Published by Springer Nature in Gene Therapy
- Vol. 32 (6) , 610-620
Rapid detection of AAV8 binding antibodies in gene therapy candidates: development of a point-of-care approach
Preexisting anti-AAV antibodies pose a significant challenge to the success of Adeno-associated Virus (AAV) mediated gene therapies, as they can diminish therapeutic effectiveness, restrict patient eligibility for treatment, and cause serious health issues during treatment. This study introduces the first point-of-care (POC) test for the rapid, quantitative detection of AAV8 binding antibodies in patients’ plasma, serum, and blood, leveraging Chembio’s Dual Path Platform (DPP) technology. The DPP AAV8 Total Antibody (TAb) assay delivers results within 20 min from sample addition, with a dynamic range of 0-32 µg/ml when evaluated with purified human polyclonal antibodies that bind to AAV8, with reasonable specificity and sensitivity relative to Chembio’s AAV8 TAb ELISA (R² = 0.90). Moreover, the assay demonstrated strong correlations with Chembio’s AAV8 neutralizing antibody (NAb) ELISA and cell-based NAb assays (R² = 0.97 in plasma) (Cell-based assay adapted from BioAgilytix EU protocol). This rapid and reliable test can facilitate the screening of potential gene therapy patients for pre-existing antibodies that bind to AAV8 and assess their suitability for AAV8-mediated gene therapy.
- Open Access
- 7 August 2020
- Published by OAE Publishing Inc. in Journal of Cancer Metastasis and Treatment
- Vol. 2020
Early detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.
- 7 August 2020
- Published by OAE Publishing Inc. in Journal of Cancer Metastasis and Treatment
- Vol. 2020
Open AccessEarly detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.